Peptide Pain Management

Clear evidence for people who are tired of being passed around.

Home / Find your pain / Peptides and aging

Can older adults take peptides safely?

Bottom line: Yes—some peptide medicines can be appropriate for older adults, and age alone does not rule them out. But “peptides” is a very broad word. GLP-1 medicines have substantial human data in people over 65. SS-31 has a small but real human aging study. BPC-157, TB-500, and MOTS-c are forward-looking research candidates, but we still do not have dependable older-adult safety or benefit data for them.

GLP-1 medicines
Established medicines with older-adult trial data. The main issue is choosing the right person and protecting muscle, nutrition, and hydration.
SS-31 / elamipretide
FDA-approved only for Barth syndrome. A 39-person trial found a short-lived improvement in mitochondrial energy production in adults aged 60–85.
BPC-157 and TB-500
Promising healing biology, but no completed controlled trial shows that either treats arthritis or improves recovery in older adults.
MOTS-c
A 120-person metabolic trial is underway, but it only enrolls adults through age 65 and has no results yet.

First: “peptide” does not describe one level of risk

A peptide is a short chain of amino acids. That tells us what it is made of—not whether it works or whether it is safe. Calling something a peptide is like calling something a vehicle: a bicycle, ambulance, and race car belong to the same broad category, but they should not be treated the same way.

There are approved peptide medicines, including semaglutide and the specialist pain medicine ziconotide. Elamipretide, also called SS-31, is now approved for one rare mitochondrial disease. BPC-157, TB-500, and MOTS-c remain experimental. A label saying “research use only” is not a safety grade; it means the product was not reviewed for use as a human medicine.

What problems might peptides eventually address?

The positive case is real. Aging commonly brings several connected problems: excess weight, insulin resistance, arthritis made worse by joint load, loss of muscle and stamina, slower recovery, and declining mitochondrial function. Peptide research is reaching each of those systems.

Can people over 65 take GLP-1 medicines?

Often, yes. The current FDA prescribing information for Wegovy includes thousands of adults aged 65–75 and hundreds aged 75 or older. It reports no overall difference in effectiveness between people over 65 and younger adults.

The risk calculation changes with frailty. Nausea, vomiting, diarrhea, constipation, low appetite, and dehydration can matter more when a person already eats little, has weak muscles, falls, or takes many medicines. In the cardiovascular trial, people aged 75 or older had more serious reactions overall than younger participants, and hip or pelvis fractures were reported more often with Wegovy than placebo.

That does not make GLP-1 treatment a bad idea for older people. It means the goal should be better health and function—not simply a smaller number on the scale. A strong plan asks how muscle strength, protein intake, hydration, balance, diabetes medicines, and kidney function will be followed.

What if triglycerides are high? High triglycerides are not listed as a Wegovy contraindication. But the exact number changes the conversation. The American College of Cardiology defines severe triglycerides as 500 mg/dL or higher, especially 1,000 mg/dL or higher, where pancreatitis prevention becomes urgent.

Because GLP-1 labels also warn about acute pancreatitis, a clinician may want to address very high triglycerides, gallbladder or pancreatitis history, alcohol use, diabetes control, and other medicines before—or while—considering treatment. Ask for the actual fasting triglyceride value and the doctor’s specific reason. “Too high” by itself is not enough information to understand the decision.

SS-31: the most direct human aging signal

SS-31 is another name for elamipretide. In a randomized study led by physician-researcher Dr. Baback Roshanravan, 39 adults aged 60–85 with poorly functioning muscle mitochondria received one dose or placebo. The treatment increased the muscle’s ability to produce cellular energy immediately after the infusion. It did not significantly improve fatigue resistance, and the energy effect was gone by day seven.

That study is small, short, and industry-connected. Still, it matters: it shows that a mitochondria-targeted peptide can change a measured part of aging human muscle biology. In 2025, FDA approved elamipretide as Forzinity to improve muscle strength in people with Barth syndrome who weigh at least 30 kilograms. That approval does not cover ordinary aging, arthritis, fatigue, or longevity.

MOTS-c: exciting metabolism research, not an older-adult answer yet

MOTS-c is a peptide made from a small section of mitochondrial DNA. Researchers are interested in insulin sensitivity, metabolic health, and how muscle responds to energy demands.

A recruiting Phase 2a study plans to compare MOTS-c with placebo in 120 adults with prediabetes and overweight or obesity. It will measure insulin sensitivity, blood sugar, lipids, weight, and safety. That is exactly the kind of human study this field needs—but it has no results, and people older than 65 are excluded. For someone well into later life, the central safety question remains open.

BPC-157, arthritis, and blood circulation

It is too strong to say that BPC-157 is known to “mess with blood circulation.” The accurate answer is more interesting: BPC-157 clearly interacts with blood-vessel biology in laboratory and animal work, but researchers do not yet know what that means for an older human.

In cell and rat experiments, BPC-157 promoted formation of small blood vessels, activated a pathway called VEGFR2, and improved blood-flow recovery in an injured rat leg. Other animal papers describe changes in clotting, vessel narrowing and widening, and collateral circulation. Those findings could help explain a healing effect. They do not prove that BPC-157 causes bleeding, prevents clots, or safely improves circulation in people.

This uncertainty matters most for someone taking a blood thinner, living with vascular disease or a clotting disorder, facing surgery, recovering from a stroke or heart attack, or being treated for active cancer. There is no reliable human interaction study for those situations. A clinician cannot monitor a risk that an online protocol pretends does not exist.

For arthritis, BPC-157 remains a plausible experimental idea rather than an established treatment. The best current step forward is a recruiting 120-person Phase 2 hamstring-injury trial—not an arthritis trial, and not an older-adult trial.

TB-500: even less human information

TB-500 is sold as a fragment related to thymosin beta-4 and is usually discussed for tissue repair. FDA reviewers found no published human exposure study for the fragment and could not draw a dependable conclusion about safety. Evidence for full thymosin beta-4 should not automatically be assigned to every vial called TB-500.

In July 2026, an FDA advisory committee recommended BPC-157 and TB-500 for the federal 503A compounding list. That vote is meaningful, but advisory: it is not final FDA action, drug approval, or proof that the products treat arthritis.

A practical way to think about an older parent

The right question is not “Are peptides safe for old people?” It is “Does this exact product have evidence for this exact problem, and can this person tolerate the risks?”

Seven questions to take to the appointment

  1. What is the exact diagnosis we are trying to improve?
  2. What are the actual triglyceride, blood-sugar, kidney, and liver numbers?
  3. Is this an FDA-approved medicine, prescribed compounding, or a research product?
  4. Were people over 65—or people like this patient—studied?
  5. How will strength, walking, appetite, hydration, falls, and pain be measured?
  6. Could it interact with blood thinners, diabetes medicine, cancer treatment, or surgery?
  7. What result would make us continue, pause, or stop?

Our outlook: Peptides are likely to become an important part of healthier aging. GLP-1 medicines already are useful for selected older adults. SS-31 proves that mitochondrial peptide science can reach aging human muscle. BPC-157, TB-500, and MOTS-c are part of the next wave—but the honest, forward-thinking position is to demand human outcomes and monitoring while that wave develops.

Primary sources

Published and evidence reviewed August 11, 2026. This is general education, not a treatment plan for a parent or other individual. Report a correction or new study.

Next reads

Peptides for arthritis and joint pain  |  BPC-157 and pain  |  Semaglutide and knee arthritis